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Treatment with β-adrenoceptor agonists does not fully overcome the symptoms
associated with severe asthma. Serelaxin elicits potent uterine and vascular relaxation
via its cognate receptor, RXFP1, and nitric oxide (NO) signaling, and is being clinically
evaluated for the treatment of acute heart failure. However, its direct bronchodilator
efficacy has yet to be explored. Tracheal rings were prepared from male Sprague-
Dawley rats (250–350 g) and tricolor guinea pigs, and precision cut lung slices
(PCLSs) containing intrapulmonary airways were prepared from rats only. Recombinant
human serelaxin (rhRLX) alone and in combination with rosiglitazone (PPARγ agonist;
recently described as a novel dilator) or β-adrenoceptor agonists (isoprenaline,
salbutamol) were added either to pre-contracted airways, or before contraction with
methacholine or endothelin-1. Regulation of rhRLX responses by epithelial removal,
indomethacin (cyclooxygenase inhibitor), L-NAME (nitric oxide synthase inhibitor),
SQ22536 (adenylate cyclase inhibitor) and ODQ (guanylate cyclase inhibitor) were also
evaluated. Immunohistochemistry was used to localize RXFP1 to airway epithelium and
smooth muscle. rhRLX elicited relaxation in rat trachea and PCLS, more slowly than
rosiglitazone or isoprenaline, but potentiated relaxation to both these dilators. It markedly
increased β-adrenoceptor agonist potency in guinea pig trachea. rhRLX, rosiglitazone,
and isoprenaline pretreatment also inhibited the development of rat tracheal contraction.
Bronchoprotection by rhRLX increased with longer pre-incubation time, and was partially
reduced by epithelial removal, indomethacin and/or L-NAME. SQ22536 and ODQ
also partially inhibited rhRLX-mediated relaxation in both intact and epithelial-denuded
trachea. RXFP1 expression in the airways was at higher levels in epithelium than
smooth muscle. In summary, rhRLX elicits large and small airway relaxation via epithelial-
dependent and -independent mechanisms, likely via RXFP1 activation and generation
of NO, prostaglandins and cAMP/cGMP. rhRLX also enhanced responsiveness to other
dilators, suggesting its potential as an alternative or add-on therapy for severe asthma.
Keywords: airway, β-adrenoceptor agonist, bronchodilation, epithelium, precision-cut lung slice, relaxin,
rosiglitazone, trachea
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INTRODUCTION
Asthma is a chronic inflammatory disease of the airways, affecting
300 million world-wide (Masoli et al., 2004). Recruitment of
inflammatory cells and stimulation of resident structural cells
in asthma promotes epithelial damage, goblet cell metaplasia,
fibrosis and the accumulation of airway smooth muscle (ASM)
(Mauad et al., 2007). These inflammatory and structural changes
contribute to the development of airway hyperresponsiveness
(AHR), characterized by excessive bronchoconstriction to allergic
and non-allergic stimuli (Yeganeh et al., 2013).
While treatment with the β2-adrenoceptor agonist salbutamol
(SAL) generally reverses asthma symptoms, dilator responses
in many patients may be limited by factors such as frequent
use and/or viral infection leading to tolerance and receptor
desensitization (Duechs et al., 2014; Spina, 2014). β2-
adrenoceptor agonists have also been shown to have relatively
lower efficacy in small airways in the distal lung, where increased
inflammation and AHR contributes to asthma severity (Donovan
et al., 2013; Bourke et al., 2014). Thus, it is important to identify
novel agents to reverse or inhibit the development of contraction
to act as bronchodilators or bronchoprotective agents in both
large and small airways.
Serelaxin (rhRLX or RLX) is the recombinant drug-based
version of the major stored and circulating form of the human
gene-2 relaxin hormone, which mediates its physiological actions
via activation of Relaxin Family Peptide Receptor 1 (RXFP1)
(Samuel et al., 2007). Although rhRLX is generally associated with
vascular changes in pregnancy and childbirth, its recent clinical
assessment for acute heart failure was associated with beneficial
effects on hemodynamics and reduced mortality (Teerlink et al.,
2013). These findings were consistent with rhRLX-enhanced
vasorelaxation in isolated rodent small renal and mesenteric
arteries (McGuane et al., 2011; Leo et al., 2014) and human
gluteal and subcutaneous resistance arteries (Fisher et al., 2002;
McGuane et al., 2011). rhRLX has also been shown to influence
gastrointestinal motility in mice via the generation of nitric oxide
(NO) from an intact epithelial layer (Baccari et al., 2013).
Of relevance to asthma, chronic in vivo administration of
rhRLX inhibited fibrosis and the development of AHR in a mouse
model of ovalbumin-induced allergic airways disease (AAD)
mimicking key features of asthma (Royce et al., 2009, 2013a).
Although rhRLX is able to exert protective effects in the lung,
and has also been identified as a safe and efficacious relaxant
of vascular and uterine smooth muscle (Bani et al., 1998; Tan
et al., 1998), its acute effects on airway contraction have yet to
be characterized.
Another potential novel bronchodilator of interest is
rosiglitazone (RGZ), originally identified as a potent agonist
of peroxisome proliferator activated receptor γ (PPARγ).
RGZ has recently been shown to elicit acute airway relaxation
independently of PPARγ activation in mouse precision cut
lung slices (PCLS) (Donovan et al., 2014) and mouse trachea
(Donovan et al., 2015). Furthermore, RGZ was more efficacious
than β2-adrenoceptor agonists in mouse airways, albeit at lower
potency (Donovan et al., 2014). Like rhRLX, RGZ has been
shown to inhibit fibrosis and the development of AHR in mouse
models of allergic AAD (Honda et al., 2004; Ward et al., 2004;
Donovan et al., 2012).
Given this background, the aims of this study were to assess
the potential bronchodilator and bronchoprotective effects of
rhRLX in comparison to RGZ and the β-adrenoceptor agonists
salbutamol and isoprenaline (ISO). We hypothesized that rhRLX
would both reverse established airway contraction and inhibit
the development of contraction, with potential for additivity with
these other dilators.
MATERIALS AND METHODS
Materials
Acetylcholine (ACh), methacholine (MCh), substance P,
isoprenaline (ISO), salbutamol (SAL), and Nω-nitro-L-arginine
methyl ester (L-NAME) (all from Sigma-Aldrich, St. Louis, MO,
USA); endothelin-1 (ET-1, GenScript, Piscatawa, NJ, USA);
indomethacin and rosiglitazone (RGZ) (both from Cayman
Chemical, Ann Arbor, MI, USA); recombinant human gene-2
relaxin (serelaxin/ rhRLX, kindly provided by Novartis AG,
Basel, Switzerland).
Animals and Tissue Collection
All procedures were approved by a Monash University Animal
Ethics Committee (AEC number: MARP2/2014/066), which
adheres to the Australia Code of Practice for the Care and Use of
Animals for Scientific Purposes. Male Sprague-Dawley rats (250–
350 g) (Monash University Animal Services, Melbourne, VIC,
Australia) and Tricolor guinea pigs (8–10 weeks) (Pipers, Cowra,
NSW, Australia) were housed in the Animal Facility, Monash
University and maintained on a fixed 12 h light, 12 h dark lighting
schedule, with free access to food and water at all times.
Rats were humanely euthanized by sodium pentobarbitone
overdose (60 mg/mL administered i.p. at a volume of 1 mL per
100 g body weight) for preparation of tracheal tissue and PCLS.
Guinea pigs were gently restrained and stunned by a single blow
to the head. Loss of consciousness was confirmed by the lack of
withdrawal reflex, followed by immediate exsanguination of the
carotid artery.
Myograph Experiments
Trachea were quickly dissected and mounted in Krebs-Henseleit
(59 mM NaCl, 2.3 mM KCl, 0.69 mM MgSO4·7H2O, 2.5 mM
CaCl2·6H2O, 0.6 mM KH2PO, 10 mM EDTA, 25 mM
NaHCO3, and 6 mM glucose) buffer solution for experiments
using myograph (Danish MyoTechnology, Arthuus Denmark,
5 ml bath for rat trachea) or standard organ baths (10 ml
bath for guinea pig trachea). Tissues were set to optimum
resting tension for maximum development of contraction to
potassium physiological salt solution (KPSS; 123.7 mM K+).
A maximal contraction to ACh (30 µM) was also obtained in
all tissues. To assess airway relaxation, cumulative additions of
MCh were made to establish a submaximal contraction (50–
70% of ACh maximum). Concentration-response curves were
then constructed to rhRLX, RGZ, ISO, or SAL or selected
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concentrations of rhRLX (0.1 µM), RGZ (10, 100 µM) or ISO
(1, 10 µM) were added alone or in combination.
To assess potential inhibition of airway contraction, trachea
were pre-incubated with selected concentrations of rhRLX
(0.1 µM), RGZ (100 µM), or ISO (10 µM) for 30 min prior
to the construction of cumulative MCh or ET-1 concentration-
response curves. The contribution of epithelial-derived factors
to inhibition of airway contraction was assessed in trachea
pre-incubated in the absence or presence of rhRLX (0.1 µM)
for 2 h. The bath solution was then either left or replaced
before concentration-response curves were generated to ET-1.
Alternatively, the epithelium was removed by gentle agitation
of the lumen using a wooden toothpick and confirmed by loss
of relaxation to the epithelial-dependent dilator substance P
(1 µM) and H&E staining of tracheal sections after experiments.
The contribution of NO and cyclooxygenase (COX)-derived
mediators was assessed using the NO synthase (NOS) inhibitor,
L-NAME (100 µM) and/or the COX inhibitor, indomethacin
(3 µM) added during the rhRLX pre-incubation period before
ET-1 curves.
Finally, SQ22536 (10 µM) and/or ODQ (1 µM), inhibitors
of adenylate cyclase and guanylate cyclase respectively, were
added to both intact and denuded trachea before a submaximal
contraction to MCh was established for assessment of relaxation
to rhRLX (0.1 µM).
Precision Cut Lung Slice (PCLS)
Experiments
Precision cut lung slice were prepared with minor modifications
from previously published methods (Bourke et al., 2014;
Donovan et al., 2014). Rats were euthanized as described
previously and dissected to expose the heart and trachea. Heparin
sodium (500IU) was injected into the left ventricle to empty
the lungs of blood before cannulation. Trachea were cannulated
with a catheter containing two ports (20 G Intima, Becton
Dickinson, VIC, Australia) and lungs were inflated with ∼10 mL
agarose gel (2% in 1x HBSS at 37◦C), followed by a bolus of
∼3 mL air. Lungs were cooled by bathing in cold HBSS/HEPES
and the rats were then kept at 4◦C to allow the agarose to
solidify, before the lungs were removed. The upper right lobe
was isolated and adhered with cyanocrylate to a mounting
plate in a vibratome (Compresstome, Precisionary Instruments,
Greenville, NC, USA). PCLS of 200 µm thickness were prepared
and transferred into cell culture plates containing DMEM,
supplemented with 1% penicillin-streptomycin and incubated for
24 h (37◦C, 5% CO2) prior to experiments.
Precision cut lung slice were transferred to HBSS/HEPES
and mounted in custom-made perfusion chambers (∼100 µL
volume). A viable airway (∼200 µm diameter) was selected
from each slice based on the presence of an intact layer of
epithelial cells with ciliary activity. PCLS were perfused at a
constant rate (∼0.5 mL/min) through an eight-channel gravity-
fed perfusion system under vacuum. Slices were initially perfused
with MCh (0.3 µM) to establish a submaximal pre-contraction,
then perfused with MCh in combination with rhRLX (0.1µM) or
ISO (10 µM). Perfusion was then stopped to permit assessment
of airway responses to MCh in the presence of dilator under static
conditions.
Phase contrast microscopy was conducted using an inverted
microscope (Nikon Ti-U, Melville, NY, USA) to observe drug-
induced airway changes, employing 10X objective lens, zoom
adapter, reducing lens and camera (CCD camera model TM-
62EX; Pulnix, Takex, Japan). Changes in airway lumen area
were captured as digital images (744 × 572 pixels) in time
lapse (0.5 Hz) using image acquisition software (Video Savant;
IO Industries, Inc., London, ON, Canada). Obtained files were
converted to TIFF files and analyzed using NIH/Scion software
(Scion Corporation; download www.scioncorpcom).
Immunohistochemistry
Lungs were dissected whole and fixed in neutral buffered
formalin before being embedded in paraffin wax. Sections (5µm)
were cut and mounted on SuperFrost PLUS slides (Menzel-
Gläser, Braunschweig, Germany). Procedures for bright field
immunohistochemistry are detailed in (Jelinic et al., 2014). Lung
sections were incubated overnight at 4◦C with 3 µg/ml rat
RXFP1 antiserum (#107, raised against amino acid residues
107–119 of the rat RXFP1 protein) or preimmune serum
(rabbit IgG). Immunoreactivity was detected using the MACH
2TM system (Biocare Medical, Concord, CA, USA) and 3, 3′
diaminobenzidine (DAB) as the chromagen substrate (Vector
Laboratories, Burlingame, CA, USA). The rat RXFP1 antibody
used has previously been shown to be selective, with no cross-
reactivity to another relaxin-family peptide receptor (RXFP2)
(Jelinic et al., 2014).
Statistical Analysis
Contraction was normalized to the maximum ACh contraction
for MCh or the KPSS response for ET-1 in trachea, or expressed
as % initial airway area in PCLS. Relaxation was expressed as %
of the MCh submaximal pre-contraction. All data are expressed
as the mean ± SEM. Non-linear regression of concentration-
response curves to obtain fitted maxima and pEC50 values where
possible. Results were analyzed via t-test or one-way ANOVA
for multiple comparisons between groups as appropriate; where
statistical significance was accepted at P < 0.05. All data analysis
was performed using GraphPad Prism v6 (GraphPad Software,
San Diego, CA, USA).
RESULTS
rhRLX, RGZ, and ISO Elicit Relaxation of
Rat Trachea
Dilator effects of rhRLX, RGZ, and ISO in rat trachea were
compared after pre-contraction to similar submaximal levels
with MCh (300 nM), measuring changes in isometric force in
a static organ bath (5 ml volume; Figure 1A). When added
at 5–10 min intervals, rhRLX did not cause any relaxation up
to 0.1 µM, the highest concentration available (Figure 1B).
In contrast, RGZ and ISO induced concentration-dependent
relaxation (fitted maximum % relaxation: ISO 45.6 ± 5.3; RGZ
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FIGURE 1 | rhRLX, RGZ, and ISO elicit relaxation of rat trachea. Rat trachea were mounted under isometric conditions for optimum development of
contraction. Trachea were (A) precontracted with MCh, prior to preparation of concentration-response curves to rhRLX (RLX), RGZ, or ISO. (B) Representative
traces show relaxation to RLX, RGZ, and ISO after MCh, as well as a time control for MCh alone. (C) Relaxation responses and time to maximum relaxation to single
additions of RLX (0.1 µM), RGZ (100 µM), or ISO (1 µM) were also assessed. Extent of relaxation is expressed as % of submaximal MCh pre-contraction, with
relaxation time expressed in min (mean ± SEM for n = 4 per group).
138.1 ± 30.0; P < 0.05). When compared to RGZ, ISO was more
potent (pEC50: ISO 8.0± 0.3; RGZ 4.7± 0.2; P< 0.001), but only
RGZ elicited complete relaxation (Figure 1A).
When the highest concentrations of each drug tested were
allowed to remain in contact with the pre-contracted trachea,
marked relaxation to rhRLX, as well as to RGZ and ISO, became
evident. Representative traces show the effects of addition of
rhRLX (0.1 µM), RGZ (100 µM), and ISO (1 µM) relative to
a time control showing maintained contraction to MCh alone
over 200 min (Figure 1B). Partial relaxation to rhRLX occurred
at slower rate than either RGZ or ISO, which caused near
complete and partial tracheal relaxation within approximately 50
and 5 min respectively (Figures 1B,C). Notably, the extent of
relaxation to 0.1 µM rhRLX-mediated (% relaxation: 52 ± 15%)
was comparable to the maximal ISO-induced airway relaxation
(50± 9%).
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FIGURE 2 | rhRLX potentiates relaxation to β-adrenoceptor agonists. Trachea were precontracted with MCh, prior to measurement of relaxation responses in
the absence and presence of rhRLX (100 nM) to ISO (0.001–10 µM) in (A) rat and (B) guinea pig trachea or SAL (0.001–10 µM) in (C) guinea pig trachea. Extent of
relaxation is expressed as % of submaximal MCh pre-contraction (mean ± SEM for n = 4–5 per group).
rhRLX Potentiates Tracheal Relaxation to
β-Adrenoceptor Agonists and RGZ
The combined effects of rhRLX and β-adrenoceptor agonists
were explored. In rat trachea, where activation of both β1 and
β2 adrenoceptors contributes to relaxation, ISO alone did not
elicit complete relaxation, and the apparent leftward shift in its
concentration-response in the presence of rhRLX did not reach
significance (potency P = 0.11; efficacy P = 0.08, n = 4–6,
Figure 2A).
As in rat trachea, rhRLX alone did not cause rapid relaxation
of guinea pig trachea (data not shown). Consistent with the
predominant role of β2-adrenoceptor in guinea pig airways, the
selective β2-adrenoceptor agonist SAL was more potent than the
β1/β2-adrenoceptor agonist ISO (pEC50: SAL 7.4 ± 0.3, ISO 6.6
± 0.2, Figures 2B,C), with both dilators causing relaxation below
the baseline prior to MCh. Pre-incubation with rhRLX resulted in
a 27.1-fold increase in ISO potency (P< 0.001, n= 4, Figure 2B)
with a similar leftward shift seen for SAL in the presence of rhRLX
(P < 0.05, n= 3, Figure 2C).
Effective single dilator concentrations of rhRLX, RGZ, and
ISO were also tested in combination in rat trachea (Figure 3).
Combining rhRLX (0.1 µM) with a submaximal concentration
of RGZ (10 µM) did not induce greater relaxation compared to
RGZ alone, while near-maximal relaxation to RGZ (100 µM) was
maintained in the presence of rhRLX (Figure 3A). However, the
addition of rhRLX markedly increased the rate of relaxation to
both concentrations of RGZ tested (P < 0.001, P < 0.01 vs. RGZ
alone, Figure 3B).
In contrast, the addition of rhRLX resulted in greater
relaxation to ISO (0.1, 10 µM) (P < 0.05 vs. ISO alone),
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FIGURE 3 | rhRLX potentiates tracheal relaxation to RGZ and ISO. Rat trachea were precontracted with MCh, prior to measurement of (A,C) relaxation
responses and (B,D) time to relaxation for rhRLX (RLX, 0.1 µM), RGZ (10, 100 µM) and ISO (0.1, 1 µM) alone and in combination. Extent of relaxation is expressed
as % of submaximal MCh pre-contraction, with relaxation time expressed in min (mean ± SEM for n = 4–5 per group). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. the
matched concentration of RGZ or ISO alone.
increasing the efficacy of both the submaximal and maximally
effective concentrations of ISO (Figure 3C). The rapid rate of
ISO-mediated relaxation was not further increased by rhRLX
(Figure 3D).
rhRLX Elicits Relaxation of Rat
Intrapulmonary Airways in Lung Slices
Using rat PCLS, the effect of rhRLX (0.1 µM) on intrapulmonary
airway contraction was also assessed, measuring changes in
airway area under perfused and static conditions in a small
volume customized chamber (∼100 µl volume). A representative
trace and sequential images of the same airway in PCLS show
that the stable contraction to MCh during continuous perfusion
over the lung slice was maintained under static conditions
(Figure 4A). rhRLX rapidly and partially reversed the MCh-
induced reduction in airway area (Figure 4B), with greater
relaxation achieved under static than perfused conditions (%
relaxation: perfused 7 ± 3%, static 64 ± 8%, P < 0.001;
Figure 4C). In contrast, relaxation to both RGZ and ISO was
similar under perfused and static conditions, causing near-
complete and partial relaxation respectively, similar to that seen
in trachea (Figure 4C).
rhRLX and RGZ, but not ISO, Inhibit the
Development of Tracheal Contraction
The bronchoprotective effects of rhRLX, RGZ, or ISO in
inhibiting the development of rat tracheal contraction were
then compared. Concentration-dependent contraction was
established, with full and partial curves obtained for MCh and
ET-1 respectively over the concentration ranges tested (Figure 5).
Pre-incubation with an effective dilator concentration of RGZ
(100 µM) for 30 min inhibited the development of contractile
responses to MCh by 90% (Figure 5B). Although, the maximum
contraction to MCh was reduced by 25% with either rhRLX
(0.1 µM) (Figure 5A) or ISO (10 µM) (Figure 5C), this did not
reach significance (Figure 5D).
rhRLX, RGZ, and ISO all significantly inhibited contraction
to ET-1 (Figures 5E–H), but only rhRLX was effective when
these drugs were compared at the same concentration (0.1 µM),
where rhRLX reduced contraction to 10−7 M ET-1 by 50%
(Figures 5E,H).
rhRLX-Mediated Inhibition of Tracheal
Contraction is Increased with Time and
Dependent on Released Factors
The effect of increasing rhRLX preincubation time on the
inhibition of development of ET-1 contraction by rhRLX was
assessed (Figure 6A). Pre-incubation with rhRLX for 120 min
completely inhibited the development of ET-1 contraction
(P < 0.01 vs. control), while 30 min preincubation only partially
inhibited contraction.
Trachea were also preincubated in the absence or presence
of rhRLX, and contraction to ET-1 assessed after the bathing
solution was replaced with buffer without rhRLX (washout).
In the absence of rhRLX preincubation, ET-1 mediated
contraction after washout was lower than without washout
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FIGURE 4 | rhRLX elicits relaxation of rat intrapulmonary airways in
lung slices. Rat lung slices were mounted in a customized chamber for
assessment of changes in intrapulmonary airway area by phase-contrast
microscopy. Airways were pre-contracted with MCh (0.3 µM) under perfused
and static conditions, in the absence and presence of rhRLX (RLX, 0.1 µM).
Representative time-course and phase-contrast images of the last frame of
(Continued)
FIGURE 4 | Continued
each condition for (A) MCh alone and (B) MCh followed by RLX (0.1 µM).
Traces show area values in pixels determined from gray-scale analysis of
images using VideoSavant. (C) Grouped data shows relaxation by RLX, RGZ
(100 µM) and ISO (10 µM) under perfused and static conditions. Data is
expressed as % relaxation of MCh pre-contraction (mean ± SEM, n = 4 per
group). ∗∗P < 0.01 vs. relaxation to RLX under perfused conditions.
(Figure 6B washout compared to Figure 6A control). When pre-
treatment with rhRLX was followed by washout, there was no
inhibition of contraction to ET-1 (Figure 6B).
rhRLX Acts via Epithelial-Dependent and
-Independent Mechanisms
To explore potential sites of action of rhRLX, expression of
its cognate receptor RXFP1 was determined in rat lungs by
immunohistochemistry. RXFP1 was localized in rat airways, with
a greater intensity of staining detected in airway epithelium than
smooth muscle (Figure 7A).
To explore potential mediators of inhibition of contraction by
rhRLX, responses to ET-1 were determined in intact trachea after
120 min preincubation with rhRLX in the absence or presence
of indomethacin and/or L-NAME. Contraction to 100 nM ET-
1 (125 ± 24% KPSS) was almost completely abolished in the
presence of rhRLX (17 ± 6% KPSS). Neither inhibitor alone
significantly reduced this inhibitory effect of rhRLX (data not
shown). However, the marked inhibition of contraction to ET-
1 by rhRLX was reduced in the presence of the combination of
indomethacin and L-NAME (56 ± 7% KPSS, P < 0.01 cf. ET-
1+rhRLX alone) (Figure 7B). This implicates both COX- and
NOS-dependent pathways in the inhibitory effect of rhRLX on
contraction.
The tracheal epithelium was then removed in order to
assess epithelial-dependence. Denudation was confirmed by
conventional hematoxylin staining of formalin-fixed sections
(data not shown) and reduced responsiveness to substance P (%
relaxation: intact 92.4 ± 2.7%; denuded 10.1 ± 4.0, P < 0.01). In
contrast to results obtained in intact trachea (control, Figure 7A),
preincubation with rhRLX for 120 min only partially inhibited
contraction to ET-1 following epithelial removal (Figure 7C).
The effects of epithelial removal on relaxation to rhRLX
following pre-contraction with MCh was also assessed
(Figure 7D). The level of MCh pre-contraction was similar
in epithelial -intact and -denuded trachea (1mN: intact
2.4± 0.1, denuded 2.2± 0.7, NS). Although relaxation to rhRLX
(0.1µM) was reduced by 40% with epithelial removal, a small but
significant reversal of the contraction to MCh was still evident
(Figure 7D). Inhibition of adenylate cyclase and guanylate
cyclase, with SQ22536 and ODQ respectively, reduced relaxation
to rhRLX in both intact and epithelial-denuded trachea.
DISCUSSION
This study provides the first evidence that rhRLX is an effective
bronchodilator and bronchoprotective agent in rat and guinea
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FIGURE 5 | rhRLX and RGZ, but not ISO, inhibit the development of tracheal contraction. The effects of pretreatment with rhRLX (RLX), RGZ and ISO
(30 min) on the development of contraction to MCh (left panels) and ET-1 (right panels) were assessed, testing (A,E) RLX (0.1 µM), (B,F) RGZ (0.1, 100 µM), and
(C,G) ISO (0.1, 1 µM). For clarity, the same control data is shown on panels (A–C) for MCh and panels E-G for ET-1. (D) Maximum contraction to MCh determined
from fitted concentration-responses curves using GraphPad Prism. (H) Contraction to the highest tested concentration of ET-1 (0.1 µM). All responses are
expressed as % KPSS standard contraction (mean ± SEM, n = 4–5 per group). ∗P < 0.05, ∗∗P < 0.01 vs. MCh or ET-1 alone.
pig airways. Compared to the β-adrenoceptor agonist ISO and
the novel dilator RGZ, rhRLX induced slower relaxation in
precontracted rat trachea, with more rapid relaxation elicited
in intrapulmonary airways in rat PCLS. The actions of rhRLX
appeared to be mediated by the release of endogenous factors
[NO, prostaglandin E2 (PGE2)], but were only partially epithelial-
dependent. rhRLX also markedly increased the potency of
β-adrenoceptor agonists ISO and SAL in guinea pig trachea,
and potentiated the extent and rate of ISO- and RGZ-mediated
relaxation respectively in rat trachea. These data suggest
that rhRLX may target alternative dilator mechanisms and
offer potential benefit in combination treatments to overcome
excessive bronchoconstriction in asthma.
Bronchodilators are the mainstay of pharmacologic therapy
for relief of asthma symptoms. However, there is an unmet
medical need for more effective treatment under conditions of
reduced responsiveness to β-adrenoceptor agonists. Identifying
novel bronchodilators that target alternative mechanisms may
offer additional benefit during a severe asthma attack or following
β-adrenoceptor desensitization (Cazzola et al., 2012).
To date, the acute effects of rhRLX in the regulation of airway
contraction have not been examined. Relaxin is a pregnancy-
related hormone, but has also been shown to elicit relaxation
of rat renal and mesenteric arteries (McGuane et al., 2011; Leo
et al., 2014). In the context of the lung, chronic treatment with
rhRLX protected against the development of airway remodeling,
reversed established fibrosis and reduced AHR in chronic AAD
models (Royce et al., 2009, 2013a).
In this study, we assessed potential dilator effects of rhRLX
in comparison with the non-selective β-adrenoceptor agonist
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FIGURE 6 | rhRLX-mediated inhibition of tracheal contraction is increased with time and dependent on released factors. ET-1-induced contractions
were assessed (A) in the absence or presence of rhRLX (RLX, 0.1 µM) following pre-treatment with for 30 and 120 min and (B) in the absence of RLX following
120 min in the absence or presence of RLX (0.1 µM) followed by replacement of the bathing solution. All responses are expressed as % KPSS standard contraction
(mean ± SEM, n = 4–7 per group).
ISO and the selective β2-adrenoceptor agonist SAL. We also
compared rhRLX with the PPARγ agonist RGZ, which was
recently shown to exert acute relaxation in mouse trachea and
small airways (Bourke et al., 2014; Donovan et al., 2014). We
utilized MCh, the gold standard to induce airway contraction
both in vitro and in vivo (Donovan et al., 2013), and ET-1, which
is upregulated in asthma (Trakada et al., 2000) and contributes to
both airway contraction and fibrosis (Ahmedat et al., 2013).
rhRLX was shown to be an effective but slowly acting
dilator, reversing an established MCh-induced contraction in
both trachea and intrapulmonary airways in PCLS. Of note, the
efficacy of the highest concentration of rhRLX tested was similar
to the maximal response to ISO, but this partial relaxation to
rhRLX in both large and small airways was achieved at a 10-
fold lower concentration than the β-adrenoceptor agonist. RGZ
was confirmed as a maximally effective dilator of rat airways,
with potency in the high µM range consistent with previous data
obtained in mice (Donovan et al., 2015). Future studies will apply
higher concentrations of rhRLX than those available for this study
to see if complete relaxation can be achieved with greater potency
and efficacy than β-adrenoceptor agonists.
Pretreatment with rhRLX (0.1 µM) also inhibited
the development of tracheal contraction to the potent
bronchoconstrictor ET-1. Similar inhibition was seen with
effective dilator concentrations of ISO and RGZ (1 and 100 µM
respectively), but only rhRLX was effective when comparisons
were made at the same concentration and preincubation
time (0.1 µM, 30 min). These findings support a greater
bronchoprotective action of rhRLX, in addition to its dilator
actions, both evident at lower concentrations than ISO and RGZ.
To identify its site of action, we showed that RXFP1, the
cognate receptor for rhRLX, was expressed in both airway
epithelium and smooth muscle. In addition, inhibition of airway
contraction and relaxation to rhRLX was reduced, but not
abolished, by epithelial removal. This is in contrast to acute
vascular relaxation to rhRLX that was abolished by endothelial
removal alone (McGuane et al., 2011) despite localization of
RXFP1 in both endothelial and vascular smooth muscle cells
(Novak et al., 2006; Jelinic et al., 2014). In the absence of a
commercially available RXFP1 antagonist to confirm receptor-
dependence, rhRLX appears to be regulating airway contraction
via actions on both epithelium and ASM. Further assessment
when RXFP1 expression is reduced or abolished, either by
using siRNA strategies ex vivo or using airway preparations
from a knockout model, should be considered to confirm this
mechanism of action.
In exploring the mechanisms underlying the effects of rhRLX,
it was notable that rhRLX-mediated relaxation was more rapid
in small airways than trachea, occurring within minutes under
static conditions. In addition, rhRLX-mediated inhibition of
tracheal contraction was almost completely abolished with
longer pretreatment, and prevented when the bathing solution
was removed prior to assessing contraction. Potentially higher
levels of endogenous mediators of relaxation released in
response to rhRLX would be present in the relatively smaller
chamber used for the lung slice studies or with longer time
of exposure. While it remains to be confirmed whether the
increased rate and extent of relaxation to RGZ and ISO
respectively seen in trachea when in combination with rhRLX
is also evident when tested in PCLS, these combined findings
are consistent with the requirement for the release and
accumulation of endogenous factors for relaxation in response to
rhRLX.
The potential identity and origin of these endogenous
mediators were then explored. In intact trachea, inhibition
of contraction by rhRLX was reduced in the presence of
the combination of the NOS inhibitor L-NAME or the
COX inhibitor indomethacin, and also by epithelial removal.
This implicates both PGE2 and NO, released from the
epithelium, as endogenous mediators contributing to the
effects of rhRLX. However, PGE2 release from ASM has
been shown to exert autocrine effects on proliferation and
cytokine release (Holgate et al., 2003). Since inhibitory effects
of rhRLX on contraction were still evident in epithelial-
denuded tissues, rhRLX may also act via RXFP1 on ASM
to increase levels of ASM-derived mediators such as PGE2
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FIGURE 7 | rhRLX acts via epithelial-dependent and -independent mechanisms. RXFP1 protein was localized in rat lungs by immunohistochemistry, and
responses to rhRLX (RLX) in epithelial-intact and -denuded trachea were compared in the absence and presence of specific inhibitors. (A) Immunoreactive RXFP1 is
predominantly localized in airway epithelium (epi) and smooth muscle (ASM). Contraction to ET-1 in (B) intact trachea under control conditions, and with RLX
(0.1 µM) in the absence and presence of INDO (3 µM) + L-NAME (100 µM) and (C) in denuded trachea in the absence and presence of RLX (0.1 µM). Responses
to ET-1 are expressed as a % of KPSS contraction. (D) Responses to RLX (0.1 µM) in intact and denuded trachea in the absence or presence of SQ22536 (10 µM)
or ODQ (1 µM), expressed as % relaxation of MCh pre-contraction. Data is expressed as mean ± SEM (n = 4–8 per group). ∗∗P < 0.01, ∗∗∗P < 0.001, vs. RLX in
intact trachea, #P < 0.05 vs. RLX in denuded trachea.
and/or exert direct effects on ASM to oppose contraction.
In recent studies, rhRLX was shown to increase prostacyclin
release to exert relaxation in vascular tissue (Jelinic et al., 2014;
Leo et al., 2014; Sarwar et al., 2016). This further suggests
that prostaglandins are key contributors to rhRLX-mediated
relaxation.
The guanylate cyclase inhibitor, ODQ and the adenylate
cyclase inhibitor SQ22536, in both intact and epithelial-denuded
trachea, reduced relaxation to rhRLX to reverse MCh-induced
contraction. This finding is also consistent with contributions of
NO and PGE2 released from epithelium and/or ASM in response
to rhRLX, as these mediators activate GC and AC respectively in
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intact tissue to oppose ASM contraction. However, rhRLX itself
has been shown to directly increase cAMP and activate PKA in
both transfected HEK cells expressing RXFP1 (Halls et al., 2007)
and bronchial epithelial cells to stimulate migration and ciliary
beat frequency (Wyatt et al., 2002). Overall, the mechanisms
driving relaxation appear to involve indirect effects of rhRLX
mediated by NO, and PGE2 and direct effects of rhRLX on both
epithelial cells and ASM.
Characterization of the mechanisms and relative efficacy of
novel dilators is necessary to support studies of their potential
benefit in combination with existing therapy with β-adrenoceptor
agonists. We have previously shown that RGZ reversed MCh-
induced contractions in mouse trachea and lung slices through
PPARγ- and epithelial-independent mechanisms involving the
attenuation of Ca2+ oscillations (Bourke et al., 2014; Donovan
et al., 2015). We assessed the effects of rhRLX in combination
with RGZ, ISO and SAL, to determine whether the mechanism of
action of rhRLX, newly identified here, would increase the extent
or rate of relaxation to RGZ or the β-adrenoceptor agonists.
Although, the combination of RGZ and rhRLX was not more
effective at eliciting relaxation in rat trachea, the response was
markedly more rapid than either treatment alone. In addition to
its epithelial-independent mechanisms, RGZ has also been shown
to inhibit PGE2 breakdown (Henry et al., 2005), so the PGE2-
dependent pathways contributing to rhRLX-mediated relaxation
may have been further enhanced in this particular combination.
The effects of rhRLX in combination with ISO were tested
in rat trachea, where relaxation is mediated via both β1-
and β2-adrenoceptors and ISO elicits rapid but incomplete
relaxation. Under these conditions, rhRLX increased ISO-
mediated relaxation at a similar rate compared to ISO alone,
despite the slow relaxation seen with rhRLX alone. In guinea pig
trachea, complete relaxation was mediated via β2-adrenoceptor
agonism by SAL alone, overcoming the contraction due to
MCh and any endogenous contractile mediators that may have
accumulated during the experiment. SAL was more potent
than ISO, and rhRLX markedly increased the potency of both
bronchodilators. Thus, although the rapid accumulation of
cAMP in response to ISO or SAL may be maximal, the additional
ability of rhRLX to generate cGMP (via NO) may contribute to
greater relaxation to β-adrenoceptor agonists when their efficacy
is limited as in rat trachea, or increase their potency to further
enhance dilator responsiveness as in guinea pig trachea.
rhRLX therefore offers intriguing possibilities as an alternative
or additional therapy for asthma. Phase 3 clinical trials are already
underway for the use of rhRLX to treat acute heart failure,
while its safety and efficacy have been established (RELAX-
AHF trial, Teerlink et al., 2013). rhRLX has previously been
demonstrated to oppose the development of airway remodeling
and AHR, and shown to have greater anti-fibrotic effects when
used in combination with prednisolone in an experimental
model of AAD (Royce et al., 2013b). Here we demonstrate
further potential benefits of rhRLX, mediating bronchodilator
actions by mechanisms that differ from and potentially enhance
responses to β-adrenoceptor agonists. It would therefore be
of interest to assess both its bronchodilator efficacy and
potential anti-inflammatory actions in this disease context to
support its further preclinical evaluation. Future studies should
define the therapeutic potential of Serelaxin as an add-on
reliever medication for asthma, particularly when β-adrenoceptor
responsiveness is limited.
AUTHOR CONTRIBUTIONS
ML designed and performed experiments and assays, and
contributed to the writing of the manuscript. CD and MJ
performed experiments and contributed to the interpretation of
the results and the preparation of the manuscript. SR, LP, and CS
contributed to the design of experiments, interpretation of the
results and the preparation of the manuscript. JB conceived and
organized the study and was the PI, contributed to the design of
experiments, interpretation of the results, and wrote the first draft
of the manuscript.
FUNDING
This study was supported in part by a Monash University MBio
Postgraduate Discovery Scholarship to ML; a National Health &
Medical Research Council (NHMRC) of Australia Project Grant
(GNT1041575) to JB and SR; and an NHMRC Senior Research
Fellowship (GNT1041766) to CS.
ACKNOWLEDGMENT
Prof. O. D. Sherwood (Department of Physiology and Biophysics,
University of Illinois, Urbana, IL, USA) kindly supplied the rat
RXFP1 antibody (#107).
REFERENCES
Ahmedat, A., Warnken, M., Seemann, W., Mohr, K., Kostenis, E., Juergens, U.,
et al. (2013). Pro-fibrotic processes in human lung fibroblasts are driven by
an autocrine/paracrine endothelinergic system. Br. J. Pharmacol. 168, 471–487.
doi: 10.1111/j.1476-5381.2012.02190.x
Baccari, M. C., Squecco, R., and Garella, R. (2013). Relaxin and gastrointestinal
motility. Ital. J. Anat. Embryol. 1, 1–3.
Bani, D., Failli, P., Bello, M. G., Thiemermann, C., Sacchi, T. B., Bigazzi, M.,
et al. (1998). Relaxin Activates the L -Arginine – Nitric Oxide Pathway in
Vascular Smooth Muscle Cells in Culture. Hypertension 31, 1240–1247. doi:
10.1161/01.HYP.31.6.1240
Bourke, J. E., Bai, Y., Donovan, C., Esposito, J. G., Tan, X., and Sanderson, M. J.
(2014). Novel small airway bronchodilator responses to rosiglitazone in mouse
lung slices. Am. J. Respir. Cell Mol. Biol. 50, 748–756. doi: 10.1165/rcmb.2013-
0247OC
Cazzola, M., Page, C. P., Calzetta, L., and Matera, M. G. (2012). Pharmacology
and therapeutics of bronchodilators. Pharmacol. Rev. 64, 450–504. doi:
10.1124/pr.111.004580
Donovan, C., Bailey, S. R., Tran, J., Haitsma, G., Ibrahim, Z. A.,
Foster, S. R., et al. (2015). Rosiglitazone elicits in vitro relaxation in
airways and precision cut lung slices from a mouse model of chronic
allergic airways disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 309,
L1219–L1228.
Frontiers in Pharmacology | www.frontiersin.org 11 October 2016 | Volume 7 | Article 406
fphar-07-00406 October 25, 2016 Time: 14:33 # 12
Lam et al. Serelaxin is a Novel Bronchodilator
Donovan, C., Royce, S. G., Esposito, J., Tran, J., Ibrahim, Z. A., Tang, M. L. K.,
et al. (2013). Differential effects of allergen challenge on large and small airway
reactivity in mice. PLoS ONE 8:e74101. doi: 10.1371/journal.pone.0074101
Donovan, C., Simoons, M., Esposito, J., Ni Cheong, J., Fitzpatrick, M., and Bourke,
J. E. (2014). Rosiglitazone is a superior bronchodilator compared to chloroquine
and β-adrenoceptor agonists in mouse lung slices. Respir. Res. 15:29. doi:
10.1186/1465-9921-15-29
Donovan, C., Tan, X., and Bourke, J. E. (2012). PPARγ ligands regulate
noncontractile and contractile functions of airway smooth muscle: implications
for asthma therapy. PPAR Res. 2012:809164. doi: 10.1155/2012/809164
Duechs, M. J., Tilp, C., Tomsic, C., Gantner, F., and Erb, K. J. (2014). Development
of a novel severe triple allergen asthma model in mice which is resistant to
dexamethasone and partially resistant to TLR7 and TLR9 agonist treatment.
PLoS ONE 9:e91223. doi: 10.1371/journal.pone.0091223
Fisher, C., MacLean, M., Morecroft, I., Seed, A., Johnston, F., Hillier, C., et al.
(2002). Is the pregnancy hormone relaxin also a vasodilator peptide secreted by
the heart? Circulation 106, 292–295. doi: 10.1161/01.CIR.0000025630.05387.45
Halls, M. L., Bathgate, R. A. D., and Summers, R. J. (2007). Comparison of
signaling pathways activated by the relaxin family peptide receptors, RXFP1
and RXFP2, using reporter genes. J. Pharmacol. Exp. Ther. 320, 281–290. doi:
10.1124/jpet.106.113225
Henry, P. J., Aprile, A. D., Self, G., Hong, T., and Mann, T. S. (2005). Inhibitors of
prostaglandin transport and metabolism augment protease-activated receptor-
2-mediated increases in prostaglandin E2 levels and smooth muscle relaxation
in mouse isolated trachea. J. Pharmacol. Exp. Ther. 314, 995–1001. doi:
10.1124/jpet.105.086124
Holgate, S. T., Peters-Golden, M., Panettieri, R. A., and Henderson, W. R.
(2003). Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle
function, and remodeling. J. Allergy Clin. Immunol. 111, S18–S36. doi:
10.1067/mai.2003.25
Honda, K., Marquillies, P., Capron, M., and Dombrowicz, D. (2004). Peroxisome
proliferator-activated receptor γ is expressed in airways and inhibits features
of airway remodeling in a mouse asthma model. J. Allergy Clin. Immunol. 113,
882–888. doi: 10.1016/j.jaci.2004.02.036
Jelinic, M., Leo, C.-H., Post Uiterweer, E. D., Sandow, S. L., Gooi, J. H., Wlodek,
M. E., et al. (2014). Localization of relaxin receptors in arteries and veins, and
region-specific increases in compliance and bradykinin-mediated relaxation
after in vivo serelaxin treatment. FASEB J. 28, 275–287. doi: 10.1096/fj.13-
233429
Leo, C. H., Jelinic, M., Parkington, H. C., Tare, M., and Parry, L. J. (2014).
Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes
rapid and sustained bradykinin-mediated vasorelaxation. J. Am. Heart Assoc. 3,
e000493. doi: 10.1161/JAHA.113.000493
Masoli, M., Fabian, D., Holt, S., and Beasley, R. (2004). The global burden of
asthma?: executive summary of the GINA Dissemination Committee Report.
Allergy 59, 469–478. doi: 10.1111/j.1398-9995.2004.00526.x
Mauad, T., Bel, E., and Sterk, P. (2007). Asthma therapy and airway
remodeling. J. Allergy Clin. Immunol. 120, 997–1009. doi: 10.1016/j.jaci.2007.
06.031
McGuane, J. T., Debrah, J. E., Sautina, L., Jarajapu, Y. P. R., Novak, J., Rubin,
J. P., et al. (2011). Relaxin induces rapid dilation of rodent small renal and
human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology
152, 2786–2796. doi: 10.1210/en.2010-1126
Novak, J., Parry, L. J., Matthews, J. E., Kerchner, L. J., Indovina, K., Hanley-
Yanez, K., et al. (2006). Evidence for local relaxin ligand-receptor expression
and function in arteries. FASEB J. 20, 2352–2362. doi: 10.1096/fj.06-6263com
Royce, S. G., Miao, Y. R., Lee, M., Samuel, C. S., Tregear, G. W., and Tang, M. L. K.
(2009). Relaxin reverses airway remodeling and airway dysfunction in allergic
airways disease. Endocrinology 150, 2692–2699. doi: 10.1210/en.2008-1457
Royce, S. G., Moodley, Y., and Samuel, C. S. (2013a). Novel therapeutic strategies
for lung disorders associated with airway remodelling and fibrosis. Pharmacol.
Ther. 141, 250–260. doi: 10.1016/j.pharmthera.2013.10.008
Royce, S. G., Sedjahtera, A., Samuel, C. S., and Tang, M. L. K. (2013b). Combination
therapy with relaxin and methylprednisolone augments the effects of either
treatment alone in inhibiting subepithelial fibrosis in an experimental model
of allergic airways disease. Clin. Sci. 124, 41–51. doi: 10.1042/CS20120024
Samuel, C. S., Lekgabe, E. D., and Mookerjee, I. (2007). “The effects if relaxin on
extracellular matrix remodeling in health and fibrotic disease,” in Relaxin and
Related Peptides, ed. A. I. Agoulnik (New York, NY: Springer), 88–103.
Sarwar, M., Samuel, C. S., Bathgate, R. A., Stewart, D. R., and Summers, R. J. (2016).
Enhanced serelaxin signalling in co-cultures of human primary endothelial and
smooth muscle cells. Br. J. Pharmacol. 173, 484–496. doi: 10.1111/bph.13371
Spina, D. (2014). Current and novel bronchodilators in respiratory disease. Curr.
Opin. Pulm. Med. 20, 73–86. doi: 10.1097/MCP.0000000000000012
Tan, Y. Y., Wade, J. D., Tregear, G. W., and Summers, R. J. (1998). Comparison of
relaxin receptors in rat isolated atria and uterus by use of synthetic and native
relaxin analogues. Br. J. Pharmacol. 123, 762–770. doi: 10.1038/sj.bjp.0701659
Teerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., Greenberg,
B. H., et al. (2013). Serelaxin, recombinant human relaxin-2, for treatment
of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
Lancet 381, 29–39.
Trakada, G., Tsourapis, S., Marangos, M., and Spiropoulos, K. (2000). Arterial
and bronchoalveolar lavage fluid endothelin-1 concentration in asthma. Respir.
Med. 94, 992–996. doi: 10.1053/rmed.2000.0890
Ward, J. E., Gould, H., Harris, T., Bonacci, J. V., and Stewart, A. G. (2004).
PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone
regulate human cultured airway smooth muscle proliferation through different
mechanisms. Br. J. Pharmacol. 141, 517–525. doi: 10.1038/sj.bjp.0705630
Wyatt, T. A., Sisson, J. H., Forgét, M. A., Bennett, R. G., Hamel, F. G., and Spurzem,
J. R. (2002). Relaxin stimulates bronchial epithelial cell PKA activation,
migration, and ciliary beating. Exp. Biol. Med. 227, 1047–1053.
Yeganeh, B., Xia, C., Movassagh, H., Koziol-White, C., Chang, Y., Al-Alwan, L.,
et al. (2013). Emerging mediators of airway smooth muscle dysfunction in
asthma. Pulm. Pharmacol. Ther. 26, 105–111. doi: 10.1016/j.pupt.2012.06.011
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Lam, Royce, Donovan, Jelinic, Parry, Samuel and Bourke. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pharmacology | www.frontiersin.org 12 October 2016 | Volume 7 | Article 406
